紫杉醇抑制犬模型创伤后喉返神经向环杓后肌再生
研究在犬喉模型中对49份半喉标本分组,观察紫杉醇预防创伤后喉返神经向环杓后肌再生的效果。结果显示紫杉醇组平均喉内收压为70.6%,高于生理盐水对照组的55.5%,其效果与长春新碱在0个月和延迟3个月注射时相同,经口与开放注射途径无差异。作者认为单次肌内注射紫杉醇耐受良好,需进一步人体研究确定临床获益程度。
要点
- 紫杉醇组平均喉内收压70.6%,高于生理盐水对照组的55.5%。
- 紫杉醇效果与长春新碱在0个月和延迟3个月注射时相同。
- 经口与开放注射途径之间无差异,单次肌内注射紫杉醇耐受良好。
核心结论
- 环杓后肌注射紫杉醇可改善喉内收强度,效果与长春新碱在神经损伤后0个月和3个月时相似,单次肌内注射耐受良好,需进一步人体研究确定临床获益程度。
研究设计与样本
- 实验动物研究,49份犬半喉标本分为五个实验组,在全身麻醉下行气管造口、喉返神经切断与修复,并于损伤前测量喉内收压。
主要发现
- 紫杉醇组平均喉内收压为70.6%,生理盐水对照组为55.5%。
- 紫杉醇的效果与长春新碱在0个月注射时相同,与延迟3个月注射时也相同。
- 经口与开放经颈注射两组之间无差异。
局限性
- 原文结论提出需进一步人体研究以确定该干预的临床获益程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: To investigate the efficacy of paclitaxel, a potent microtubule inhibitor with a more favorable therapeutic index as compared with vincristine, in preventing post-traumatic nerve regeneration of the recurrent laryngeal nerve into the posterior cricoarytenoid muscle in a canine laryngeal model. STUDY DESIGN: Experimental animal study. METHODS: Forty-nine canine hemilaryngeal specimens were divided into five experimental groups. Under general anesthesia, a tracheostomy, recurrent laryngeal nerve (RLN) transection and repair, and laryngeal adductory pressures (LAP) were measured pre-RLN injury. The approach to the posterior cricoarytenoid (PCA) muscle for neurotoxin injection was transoral or open transcervical, at 0 or 3 months. At 6 months, postinjury LAPs were measured and the animals were sacrificed at 6 months to allow for laryngeal harvesting and analysis. RESULTS: Paclitaxel demonstrated increased mean laryngeal adductory pressures (70.6%) as compared with saline control (55.5%). The effect of paclitaxel was the same as observed with vincristine at 0 months and with a delayed injection at 3 months. There was no difference between transoral or open injection groups. CONCLUSIONS: PCA muscle injection with paclitaxel resulted in improved strength of laryngeal adduction. This effect was similar to that of vincristine at both 0 and 3 months following nerve injury. A single intramuscular injection of paclitaxel was well tolerated. Additional human studies are needed to determine the degree of clinical benefit of this intervention. LEVEL OF EVIDENCE: NA Laryngoscope, 127:651-655, 2017.
引用
- Park AM, Bhatt NK, Paniello RC, et al. Paclitaxel inhibits post-traumatic recurrent laryngeal nerve regeneration into the posterior cricoarytenoid muscle in a canine model. Laryngoscope. 2016. PMID: 27900774. doi:10.1002/lary.26058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。